Stifel Nicolaus restated their buy rating on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in a research note released on Tuesday. Stifel Nicolaus currently has a $13.00 price target on the biopharmaceutical company’s stock.
Several other research firms also recently weighed in on TTPH. BMO Capital Markets restated a buy rating and issued a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Monday, May 15th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, July 6th. ValuEngine downgraded Tetraphase Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 1st. Needham & Company LLC restated a hold rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Finally, HC Wainwright assumed coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a buy rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Tetraphase Pharmaceuticals has a consensus rating of Hold and an average target price of $10.88.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 6.88 on Tuesday. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93. The stock’s market cap is $351.24 million. The firm’s 50-day moving average price is $6.33 and its 200 day moving average price is $7.26.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.07). The firm had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The business’s revenue was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.47) earnings per share. Equities analysts predict that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This report was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thestockobserver.com/2017/09/13/tetraphase-pharmaceuticals-inc-ttph-given-buy-rating-at-stifel-nicolaus.html.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the transaction, the insider now owns 17,500 shares in the company, valued at $105,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Teza Capital Management LLC grew its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,281 shares during the last quarter. Citadel Advisors LLC grew its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,496 shares during the last quarter. UBS Group AG grew its stake in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 387 shares during the last quarter. AXA purchased a new position in Tetraphase Pharmaceuticals in the second quarter valued at about $132,000. Finally, Jane Street Group LLC purchased a new position in Tetraphase Pharmaceuticals in the first quarter valued at about $181,000. Institutional investors own 41.73% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.